Cancer Biomarker Sales to Reach US$ 27 Bn by 2025; Government Funding Pivotal in Accelerating Market Growth, Says a New Fact.MR Report

The rising prevalence of cancer and extensive research in the diagnosis and treatment of cancer are driving the growth of the cancer biomarker market.

Dubai, UAE, April 01, 2020 (GLOBE NEWSWIRE) -- The global cancer biomarker market will reach a valuation of US$ 27 Bn by the end of 2025, as projected by a new Fact.MR report. The growth is primarily driven by the increasing prevalence of cancer and the subsequent investments in research and development activities. Factors further complementing the growth are favorable government funding initiatives on cancer diagnostics.

Cancer Biomarker Market: Key Findings

  • Circulating Tumor Test (CTT) and Prostate Specific Antigen (PSA) test collectively account for more than half of overall market value.
  • On the back of high cigarette smoking, lung cancer is expected to be the most common type of cancer, thereby accounting for a quarter total market share in testing.
  • North America is set to account for a large portion of the overall global revenue, on the back of heavy budget allocation by the government for cancer research and training.
  • Asia-Pacific will witness tremendous growth owing to the increasing affordability of cancer treatments in emerging economies.

Request Sample Report-

Cancer Biomarker Market: Key Driving Factors

  • Governments in developed and emerging economies are financing clinical trials, thus enabling companies to develop effective diagnostics and treatments for cancer diseases, thus giving a significant boost to the global cancer biomarker market.
  • Invigorated by technological advancements, numerous companies in the diagnostic imaging market are developing advanced, efficient, and economical equipment, and hence, are gaining traction among end-users.

Explore the complete cancer biomarkers market report with detailed market segmentation, 64 illustrative figures, and 18 data tables at –

Cancer Biomarker Market: Key Restraint

  • Major factors possessing a challenge to the rapid growth of the market are reluctance among end-users to adopt new technologies and the high cost of biomarker techniques.

Competition Landscape

Some of the key players in the global cancer biomarker market are F. Hoffmann-La Roche Ltd., Abbott Technologies & Merck & Co., Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Illumina, Inc., bioMérieux SA, Hologic, Inc., Genomic Health, Inc., and QIAGEN, among others. The market players are adopting Artificial Intelligence (to) to develop their offerings and to decode the cancer pathology.

About the Report

This 170-page study offers a detailed market forecast on the cancer biomarker market. The key categories covered in the report include Market statistics have been presented on the basis of Test Type (PSA tests, CTC tests, AFP tests, CA tests, HER2 tests, BRCA tests, ALK tests, CEA tests, EFGR mutation tests, KRAS mutation tests, and Others) and Disease Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma, etc.) across five major regions.

Explore Fact.MR’s lucid coverage of the healthcare landscape

Automated External Defibrillators Market– The automated external defibrillators market study analyses the key trends, innovations, regulatory policies, and key strategies adopted by leading players in this evolving landscape.

Atopic Dermatitis Market– The study analyses the atopic dermatitis market and offers growth opportunities in USD million across 30+ countries in six regions.

Rare Neurological Disease Treatment Market– With strong growth through 2028, the rare neurological disease market is witnessing substantial growth in a market.

About Fact.MR

Expert analysis, actionable insights, and strategic recommendations of the highly seasoned research team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the Healthcare sector across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Fact.MR's latest healthcare market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.



11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States